 |
drug-information.ru |
|Lidex Topical Solution |
| Drugs search, click the first letter of a drug name: | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 9 Home LidexGeneric Name: fluocinonide Dosage Form: Topical solution DescriptionLidex solution 0.05% is intended for topical administration. The active component is the corticosteroid fluocinonide, which is the 21-acetate ester of fluocinolone acetonide and has the chemical name pregna - 1,4 - diene - 3,20 - dione,21 - (acetyloxy) - 6,9 - difluoro - 11 - hydroxy - 16,17 - [(1 - methylethylidene)bis(oxy)] - ,(6α,11β,16α) - . It has the following chemical structure:  Lidex topical solution contains fluocinonide 0.5 mg/mL in a solution of alcohol (35%), citric acid, diisopropyl adipate, and propylene glycol. In this formulation, the active ingredient is totally in solution. Clinical PharmacologyTopical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. PharmacokineticsThe extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. A significantly greater amount of fluocinonide is absorbed from the solution than from the cream or gel formulations. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses. (See DOSAGE AND ADMINISTRATION.) Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile. Indications and UsageLIDEX® (fluocinonide) topical solution 0.05% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. ContraindicationsTopical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. PrecautionsGeneralSystemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing"s syndrome, hyperglycemia, and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, the addition of occlusive dressings, and dosage form. Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids. Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity. (See PRECAUTIONS—Pediatric Use.) This preparation is not for ophthalmic use. Severe irritation is possible if fluocinonide solution contacts the eye. If that should occur, immediate flushing of the eye with a large volume of water is recommended. If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted. As with any topical corticosteroid product, prolonged use may produce atrophy of the skin and subcutaneous tissues. When used on intertriginous or flexor areas, or on the face, this may occur even with short-term use. In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled. Information for the PatientPatients using topical corticosteroids should receive the following information and instructions:
Laboratory TestsThe following tests may be helpful in evaluating the HPA axis suppression: Carcinogenesis, Mutagenesis, and Impairment of FertilityLong-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids. Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results. Pregnancy Category CCorticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time. Nursing MothersIt is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman. Pediatric UsePediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing"s syndrome than mature patients because of a larger skin surface area to body weight ratio. Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing"s syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children. Adverse ReactionsThe following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence:
OverdosageTopically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects. (See PRECAUTIONS.) Dosage and AdministrationLIDEX® (fluocinonide) topical solution 0.05% is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted. How SuppliedLIDEX® (fluocinonide) topical solution 0.05% Store at room temperature. Avoid excessive heat, above 40°C (104°F). CAUTION: Federal law prohibits dispensing without prescription. Mfd. for: MEDICIS® 1997 MEDICIS® Dermatologics, Inc. 03517-14-01
Revised: 06/2006 Where can I get more information about Lidex Topical Solution ? We recommend to use www.Drugs.com Typical mistypes for Lidex Topical Solution kidex topical solution, pidex topical solution, oidex topical solution, ludex topical solution, ljdex topical solution, lkdex topical solution, lodex topical solution, l9dex topical solution, l8dex topical solution, lisex topical solution, lixex topical solution, licex topical solution, lifex topical solution, lirex topical solution, lieex topical solution, lidwx topical solution, lidsx topical solution, liddx topical solution, lidrx topical solution, lid4x topical solution, lid3x topical solution, lidez topical solution, lidec topical solution, lided topical solution, lides topical solution, lidex ropical solution, lidex fopical solution, lidex gopical solution, lidex yopical solution, lidex 6opical solution, lidex 5opical solution, lidex tipical solution, lidex tkpical solution, lidex tlpical solution, lidex tppical solution, lidex t0pical solution, lidex t9pical solution, lidex tooical solution, lidex tolical solution, lidex to-ical solution, lidex to0ical solution, lidex topucal solution, lidex topjcal solution, lidex topkcal solution, lidex topocal solution, lidex top9cal solution, lidex top8cal solution, lidex topixal solution, lidex topival solution, lidex topifal solution, lidex topidal solution, lidex topiczl solution, lidex topicsl solution, lidex topicwl solution, lidex topicql solution, lidex topicak solution, lidex topicap solution, lidex topicao solution, lidex topical aolution, lidex topical zolution, lidex topical xolution, lidex topical dolution, lidex topical eolution, lidex topical wolution, lidex topical silution, lidex topical sklution, lidex topical sllution, lidex topical splution, lidex topical s0lution, lidex topical s9lution, lidex topical sokution, lidex topical sopution, lidex topical sooution, lidex topical solytion, lidex topical solhtion, lidex topical soljtion, lidex topical solition, lidex topical sol8tion, lidex topical sol7tion, lidex topical solurion, lidex topical solufion, lidex topical solugion, lidex topical soluyion, lidex topical solu6ion, lidex topical solu5ion, lidex topical solutuon, lidex topical solutjon, lidex topical solutkon, lidex topical solutoon, lidex topical solut9on, lidex topical solut8on, lidex topical solutiin, lidex topical solutikn, lidex topical solutiln, lidex topical solutipn, lidex topical soluti0n, lidex topical soluti9n, lidex topical solutiob, lidex topical solutiom, lidex topical solutioj, lidex topical solutioh, idex topical solution, ldex topical solution, liex topical solution, lidx topical solution, lide topical solution, lidextopical solution, lidex opical solution, lidex tpical solution, lidex toical solution, lidex topcal solution, lidex topial solution, lidex topicl solution, lidex topica solution, lidex topicalsolution, lidex topical olution, lidex topical slution, lidex topical soution, lidex topical soltion, lidex topical soluion, lidex topical soluton, lidex topical solutin, lidex topical solutio, ildex topical solution, ldiex topical solution, liedx topical solution, lidxe topical solution, lide xtopical solution, lidext opical solution, lidex otpical solution, lidex tpoical solution, lidex toipcal solution, lidex topcial solution, lidex topiacl solution, lidex topicla solution, lidex topica lsolution, lidex topicals olution, lidex topical oslution, lidex topical sloution, lidex topical soultion, lidex topical soltuion, lidex topical soluiton, lidex topical solutoin, lidex topical solutino, llidex topical solution, liidex topical solution, liddex topical solution, lideex topical solution, lidexx topical solution, lidex topical solution, lidex ttopical solution, lidex toopical solution, lidex toppical solution, lidex topiical solution, lidex topiccal solution, lidex topicaal solution, lidex topicall solution, lidex topical solution, lidex topical ssolution, lidex topical soolution, lidex topical sollution, lidex topical soluution, lidex topical soluttion, lidex topical solutiion, lidex topical solutioon, lidex topical solutionn, etc.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||